LONG-TERM HEALTH RISK AFTER BREAST-CANCER RADIOTHERAPY: OVERVIEW OF PASSOS METHODOLOGY AND SOFTWARE.


Journal

Radiation protection dosimetry
ISSN: 1742-3406
Titre abrégé: Radiat Prot Dosimetry
Pays: England
ID NLM: 8109958

Informations de publication

Date de publication:
01 May 2019
Historique:
pubmed: 7 12 2018
medline: 5 6 2019
entrez: 7 12 2018
Statut: ppublish

Résumé

Breast-cancer radiotherapy reduces the recurrence rates and improves patient survival. However, it also increases the incidence of second cancers and of heart disease. These radiation-induced long-term health risks become increasingly important with improved cure rates and prolonged patient survival. Radiation doses to nearby as well as distant organs strongly vary between different irradiation techniques and among individual patients. To provide personalized lifetime risk estimates, the German national project PASSOS combines individual anatomy, dosimetric estimates, organ-specific low- and high-dose risk models and personal risk factors such as smoking. A dedicated software tool is under development to assist clinical decision-making processes.

Identifiants

pubmed: 30520982
pii: 5231890
doi: 10.1093/rpd/ncy219
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

259-263

Informations de copyright

© The Author(s) 2018. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

Auteurs

Markus Eidemüller (M)

Helmholtz Zentrum München GmbH, German Research Center for Environmental Health, Institute of Radiation Protection, Ingolstädter Landstr. 1, Neuherberg, Germany.

Cristoforo Simonetto (C)

Helmholtz Zentrum München GmbH, German Research Center for Environmental Health, Institute of Radiation Protection, Ingolstädter Landstr. 1, Neuherberg, Germany.

Pavel Kundrát (P)

Helmholtz Zentrum München GmbH, German Research Center for Environmental Health, Institute of Radiation Protection, Ingolstädter Landstr. 1, Neuherberg, Germany.

Alexander Ulanowski (A)

Helmholtz Zentrum München GmbH, German Research Center for Environmental Health, Institute of Radiation Protection, Ingolstädter Landstr. 1, Neuherberg, Germany.

Elena Shemiakina (E)

Helmholtz Zentrum München GmbH, German Research Center for Environmental Health, Institute of Radiation Protection, Ingolstädter Landstr. 1, Neuherberg, Germany.

Denise Güthlin (D)

Helmholtz Zentrum München GmbH, German Research Center for Environmental Health, Institute of Radiation Protection, Ingolstädter Landstr. 1, Neuherberg, Germany.

Hannes Rennau (H)

Klinik und Poliklinik für Strahlentherapie, Universitätsmedizin Rostock, Südring 75, Rostock, Germany.

Julia Remmele (J)

Klinik für Strahlentherapie, Universität Leipzig, Stephanstr. 9a, Leipzig, Germany.

Guido Hildebrandt (G)

Klinik und Poliklinik für Strahlentherapie, Universitätsmedizin Rostock, Südring 75, Rostock, Germany.

Ulrich Wolf (U)

Klinik für Strahlentherapie, Universität Leipzig, Stephanstr. 9a, Leipzig, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH